Summit Therapeutics (SMMT) - 2025 Q3 - Quarterly Report
Summit Therapeutics (US:SMMT)2025-10-20 11:51UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36866 Summit Therapeutics Inc. (Exact name of registrant as specified in its charter) _____________________ Delaware 37-1979717 (State or other jurisdiction of incorporation or organization) 601 Brickell Key Drive, Sui ...